CGT

The FDA has approved more than 40 cellular and gene therapy products to date, but there is a lack of ...

MAY 23, 2025

Amidst a lack of regulation to mitigate the risks GCTs pose to healthcare workers, a proposed standard operating ...

APRIL 5, 2025

It takes a village for health systems to fully benefit from high-cost specialty medications, according to a new ...

FEBRUARY 10, 2025

It takes a village for health systems to fully benefit from high-cost specialty medications, according to a new ...

JANUARY 9, 2025

An increase in rare/ultra-orphan treatments, along with a boom in cell and gene therapies and ambulatory infusion ...

DECEMBER 17, 2024

Manufacturing of novel cell and gene therapy products is extremely complex and patient-specific, so it can be a ...

AUGUST 28, 2024

At millions of dollars per dose, CGT treatments pose demanding procurement and reimbursement challenges for U.S. ...

JULY 17, 2024

Before pharmacists at UC Davis Health implemented a streamlined process to approve and institute cell and gene ...

MAY 31, 2024

Hemophilia is an X chromosome–linked genetic bleeding disorder caused by absent or defective clotting factor, ...

MAY 30, 2024

More than 20 gene therapies are projected to be approved by the end of 2025, making it imperative that facilities ...

MAY 2, 2024

The FDA approved Lenmeldy, the first gene therapy for children with presymptomatic late infantile, presymptomatic ...

MARCH 21, 2024